Precipio, Inc. (PRPO)
USD 7.32
(15.26%)
USD 7.32
(15.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.62 Million USD | 40.45% |
| 2022 | -12.79 Million USD | -33.12% |
| 2021 | -9.61 Million USD | -5.11% |
| 2020 | -9.14 Million USD | 2.74% |
| 2019 | -9.4 Million USD | 32.4% |
| 2018 | -13.91 Million USD | 10.31% |
| 2017 | -15.51 Million USD | -98.38% |
| 2016 | -7.81 Million USD | 14.96% |
| 2015 | -9.19 Million USD | 46.92% |
| 2014 | -17.32 Million USD | -9.92% |
| 2013 | -15.75 Million USD | -65.81% |
| 2012 | -9.5 Million USD | -219.78% |
| 2011 | -2.97 Million USD | 17.72% |
| 2010 | -3.61 Million USD | -90.51% |
| 2009 | -1.89 Million USD | -415.22% |
| 2008 | -368 Thousand USD | 88.92% |
| 2007 | -3.32 Million USD | -6.1% |
| 2006 | -3.13 Million USD | -24.69% |
| 2005 | -2.51 Million USD | 91.36% |
| 2004 | -29.06 Million USD | -28.65% |
| 2003 | -22.58 Million USD | -4.11% |
| 2002 | -21.69 Million USD | -122.78% |
| 2001 | -9.73 Million USD | -2.76% |
| 2000 | -9.47 Million USD | -37.68% |
| 1999 | -6.88 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.2 Million USD | 41.71% |
| 2024 Q1 | -2.07 Million USD | -142.86% |
| 2023 Q1 | -3.02 Million USD | -30.09% |
| 2023 FY | -7.62 Million USD | 40.45% |
| 2023 Q4 | -854 Thousand USD | 41.02% |
| 2023 Q3 | -1.44 Million USD | 36.82% |
| 2023 Q2 | -2.29 Million USD | 24.26% |
| 2022 Q2 | -2.43 Million USD | 49.41% |
| 2022 FY | -12.79 Million USD | -33.12% |
| 2022 Q3 | -3.22 Million USD | -32.72% |
| 2022 Q4 | -2.32 Million USD | 27.97% |
| 2022 Q1 | -4.8 Million USD | -65.54% |
| 2021 FY | -9.61 Million USD | -5.11% |
| 2021 Q2 | -2.13 Million USD | 0.23% |
| 2021 Q3 | -2.43 Million USD | -14.4% |
| 2021 Q4 | -2.9 Million USD | -19.11% |
| 2021 Q1 | -2.13 Million USD | 5.11% |
| 2020 Q2 | -2.25 Million USD | -2.54% |
| 2020 FY | -9.14 Million USD | 2.74% |
| 2020 Q3 | -2.43 Million USD | -7.66% |
| 2020 Q4 | -2.25 Million USD | 7.4% |
| 2020 Q1 | -2.2 Million USD | 48.49% |
| 2019 FY | -9.4 Million USD | 32.4% |
| 2019 Q1 | -2.05 Million USD | 60.13% |
| 2019 Q2 | -2.29 Million USD | -11.46% |
| 2019 Q3 | -2.36 Million USD | -2.96% |
| 2019 Q4 | -4.27 Million USD | -81.0% |
| 2018 Q1 | -2.44 Million USD | 76.64% |
| 2018 FY | -13.91 Million USD | 10.31% |
| 2018 Q4 | -5.16 Million USD | -25.43% |
| 2018 Q3 | -4.11 Million USD | -88.59% |
| 2018 Q2 | -2.18 Million USD | 10.83% |
| 2017 FY | -15.51 Million USD | -98.38% |
| 2017 Q1 | -1.55 Million USD | 25.35% |
| 2017 Q2 | -801 Thousand USD | 48.49% |
| 2017 Q4 | -10.48 Million USD | -188.47% |
| 2017 Q3 | -3.63 Million USD | -353.56% |
| 2016 Q2 | -1.87 Million USD | 16.41% |
| 2016 Q4 | -2.08 Million USD | -28.74% |
| 2016 FY | -7.81 Million USD | 14.96% |
| 2016 Q1 | -2.24 Million USD | -146.1% |
| 2016 Q3 | -1.61 Million USD | 13.71% |
| 2015 Q3 | -8.92 Million USD | -221.35% |
| 2015 FY | -9.19 Million USD | 46.92% |
| 2015 Q2 | -2.77 Million USD | -4.91% |
| 2015 Q1 | -2.64 Million USD | 54.53% |
| 2015 Q4 | 4.86 Million USD | 154.52% |
| 2014 Q2 | -3.95 Million USD | -11.75% |
| 2014 FY | -17.32 Million USD | -9.92% |
| 2014 Q1 | -3.53 Million USD | 1.99% |
| 2014 Q4 | -5.82 Million USD | -45.27% |
| 2014 Q3 | -4 Million USD | -1.31% |
| 2013 FY | -15.75 Million USD | -65.81% |
| 2013 Q4 | -3.61 Million USD | 33.2% |
| 2013 Q2 | -2.92 Million USD | 23.51% |
| 2013 Q3 | -5.4 Million USD | -85.01% |
| 2013 Q1 | -3.82 Million USD | -16.89% |
| 2012 Q3 | -2.42 Million USD | -77.15% |
| 2012 Q4 | -3.26 Million USD | -34.65% |
| 2012 Q2 | -1.37 Million USD | 43.83% |
| 2012 Q1 | -2.43 Million USD | -1405.56% |
| 2012 FY | -9.5 Million USD | -219.78% |
| 2011 Q4 | -162 Thousand USD | 63.1% |
| 2011 Q3 | -439 Thousand USD | 72.97% |
| 2011 Q2 | -1.62 Million USD | -116.53% |
| 2011 Q1 | -750 Thousand USD | 44.57% |
| 2011 FY | -2.97 Million USD | 17.72% |
| 2010 Q3 | -827 Thousand USD | 21.83% |
| 2010 Q4 | -1.35 Million USD | -63.6% |
| 2010 Q2 | -1.05 Million USD | -182.13% |
| 2010 FY | -3.61 Million USD | -90.51% |
| 2010 Q1 | -375 Thousand USD | -235.38% |
| 2009 FY | -1.89 Million USD | -415.22% |
| 2009 Q1 | -1 Million USD | -5194.74% |
| 2009 Q4 | 277 Thousand USD | 169.25% |
| 2009 Q3 | -400 Thousand USD | 47.85% |
| 2009 Q2 | -767 Thousand USD | 23.76% |
| 2008 Q2 | 80 Thousand USD | -13.98% |
| 2008 Q1 | 93 Thousand USD | -53.27% |
| 2008 Q3 | -522 Thousand USD | -752.5% |
| 2008 Q4 | -19 Thousand USD | 96.36% |
| 2008 FY | -368 Thousand USD | 88.92% |
| 2007 Q3 | -1.42 Million USD | -84.68% |
| 2007 Q1 | -1.33 Million USD | -44.57% |
| 2007 FY | -3.32 Million USD | -6.1% |
| 2007 Q4 | 199 Thousand USD | 113.99% |
| 2007 Q2 | -770 Thousand USD | 42.11% |
| 2006 Q4 | -920 Thousand USD | 41.74% |
| 2006 Q2 | -302 Thousand USD | 8.76% |
| 2006 Q3 | -1.57 Million USD | -422.85% |
| 2006 Q1 | -331 Thousand USD | 48.84% |
| 2006 FY | -3.13 Million USD | -24.69% |
| 2005 FY | -2.51 Million USD | 91.36% |
| 2005 Q2 | -935 Thousand USD | 23.67% |
| 2005 Q3 | 303 Thousand USD | 132.41% |
| 2005 Q4 | -647 Thousand USD | -313.53% |
| 2005 Q1 | -1.22 Million USD | 80.36% |
| 2004 Q2 | -14.75 Million USD | -345.25% |
| 2004 Q3 | -4.75 Million USD | 67.74% |
| 2004 Q4 | -6.23 Million USD | -31.04% |
| 2004 FY | -29.06 Million USD | -28.65% |
| 2004 Q1 | -3.31 Million USD | 61.18% |
| 2003 Q2 | -4.54 Million USD | -28.35% |
| 2003 Q3 | -5.96 Million USD | -31.29% |
| 2003 Q4 | -8.53 Million USD | -43.02% |
| 2003 Q1 | -3.54 Million USD | 61.67% |
| 2003 FY | -22.58 Million USD | -4.11% |
| 2002 Q2 | -4.06 Million USD | -13.57% |
| 2002 Q4 | -9.23 Million USD | -91.26% |
| 2002 Q1 | -3.57 Million USD | -16.07% |
| 2002 FY | -21.69 Million USD | -122.78% |
| 2002 Q3 | -4.83 Million USD | -18.97% |
| 2001 Q4 | -3.08 Million USD | -27.22% |
| 2001 FY | -9.73 Million USD | -2.76% |
| 2001 Q1 | -2.01 Million USD | 2.16% |
| 2001 Q2 | -2.22 Million USD | -10.58% |
| 2001 Q3 | -2.42 Million USD | -8.76% |
| 2000 FY | -9.47 Million USD | -37.68% |
| 2000 Q1 | -3.02 Million USD | 0.0% |
| 2000 Q2 | -2.27 Million USD | 25.04% |
| 2000 Q3 | -2.11 Million USD | 6.63% |
| 2000 Q4 | -2.05 Million USD | 2.94% |
| 1999 FY | -6.88 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 92.173% |
| Biodesix, Inc. | -41.34 Million USD | 81.568% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 4.43% |
| Castle Biosciences, Inc. | -67.97 Million USD | 88.79% |
| DarioHealth Corp. | -56.18 Million USD | 86.439% |
| Exact Sciences Corporation | -215.01 Million USD | 96.456% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.695% |
| Illumina, Inc. | -1.06 Billion USD | 99.287% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 25.898% |
| iSpecimen Inc. | -11.16 Million USD | 31.778% |
| Standard BioTools Inc. | -76.6 Million USD | 90.052% |
| 23andMe Holding Co. | -321.35 Million USD | 97.629% |
| Medpace Holdings, Inc. | 336.82 Million USD | 102.262% |
| NeoGenomics, Inc. | -107.73 Million USD | 92.927% |
| Inotiv, Inc. | -81.46 Million USD | 90.646% |
| Psychemedics Corporation | -2.92 Million USD | -160.87% |
| Prenetics Global Limited | -52.51 Million USD | 85.489% |
| RadNet, Inc. | 98.69 Million USD | 107.721% |
| Sotera Health Company | 276.69 Million USD | 102.754% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -75.334% |
| Exagen Inc. | -22.83 Million USD | 66.633% |
| Natera, Inc. | -446.24 Million USD | 98.292% |
| Aspira Women's Health Inc. | -18.85 Million USD | 59.58% |
| Neogen Corporation | 58.66 Million USD | 112.989% |
| Myriad Genetics, Inc. | -123.7 Million USD | 93.84% |
| ICON Public Limited Company | 956.15 Million USD | 100.797% |
| Bionano Genomics, Inc. | -215.24 Million USD | 96.46% |
| CareDx, Inc | -101.9 Million USD | 92.522% |
| Check-Cap Ltd. | -19.28 Million USD | 60.492% |
| Twist Bioscience Corporation | -220.83 Million USD | 96.549% |
| Guardant Health, Inc. | -564.72 Million USD | 98.651% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -193.801% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 89.518% |
| Sera Prognostics, Inc. | -39.82 Million USD | 80.864% |
| OPKO Health, Inc. | -157.02 Million USD | 95.147% |
| Personalis, Inc. | -109.93 Million USD | 93.069% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 30.432% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -75.334% |
| MDxHealth SA | -27.32 Million USD | 72.115% |
| Prenetics Global Limited | -52.51 Million USD | 85.489% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 27.572% |
| Mainz Biomed B.V. | -26.64 Million USD | 71.401% |
| Trinity Biotech plc | -27.04 Million USD | 71.825% |
| Neuronetics, Inc. | -30.55 Million USD | 75.061% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 4.43% |